Dr. Deepa Jeyakumar, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 111
Licensed in California since 2012, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A121651 (first issued 2012; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
Medical groups
- UC Regents (319 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 111
- Services billed
- 568
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 475 | 69 |
| Telephone medical discussion with physician, 21-30 minutes | 127 | 16 |
| Established patient office or other outpatient visit, 30-39 minutes | 25 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Orange, CA | 104 |
| Venclexta (venetoclax) | 92 |
| Levofloxacin Other prescribers in Orange, CA | 55 |
| Posaconazole | 41 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Orange, CA | 33 |
| Cresemba (isavuconazonium sulfate) | 24 |
| Tramadol Hcl Other prescribers in Orange, CA | 23 |
| Onureg (azacitidine) | 23 |
| Potassium Chloride Other prescribers in Orange, CA | 22 |
| Lenalidomide | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $1,541 in total to this clinician.
| Amgen Inc. | $1,416 |
|---|---|
| Daiichi Sankyo Inc. | $125 |
| Consulting Fee | $1,366 |
|---|---|
| Food and Beverage | $175 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Oct 14, 2025 | Consulting Fee BLINCYTO · Oncology | $1,366 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 8 companies. The companies reported $715,234 in research payments for these studies, mostly to the institutions running them.
- IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
AbbVie Inc. · Active, not recruiting · NCT04086264 - A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AM…
Astellas Pharma Global Development - A Phase 1b Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML Who Are Unfit for Intensive Chemotherapy
Jazz Pharmaceuticals Inc. - Phase ii study of the combination of glasdegib and CPX351 in previously untreated patients with acute myelogenous leukemia with mds related changes or therapyrelated acute myeloid leukemia a university of california h…
Pfizer Inc. - Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic…
Amgen Inc. - Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06577441 - Calaspargase pegol in adults with all
Servier Bioinnovation - A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Comple…
Amgen Inc. - IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
AbbVie Inc. - A randomized, open-label, controlled, phase 2 study of pevonedistat, venetoclax, and azacitidine versus venetoclax plus azacitidine in adults with newly diagnosed acute myeloid leukemia who are unfit for intensive che…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.